Complement Protein Biomarkers for Autoimmune Flare Prediction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diagnostic methods for autoimmune diseases like lupus erythematosus lack specificity, leading to improper treatment and logistical issues in clinical trials due to false positives and undertreatment, as they fail to accurately predict flares and monitor disease activity.
Innovation Solution
The use of complement proteins and their split products, particularly the complement activation potential, to predict flares and monitor disease activity in autoimmune diseases by determining the levels of iC3b, total C3, and C4, allowing for personalized treatment adjustments and improved diagnostic accuracy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current diagnostic methods are used to monitor autoimmune disease activity, then treatment can be provided, but the diagnosis lacks specificity leading to false positives and improper treatment
Solution Approach 1:
The patent changes the diagnostic parameter from non-specific inflammatory markers to complement protein levels and ratios (C3, C4, iC3b, sC5b-9), which specifically reflect complement system activation associated with autoimmune flares. This parameter change enables precise detection of true disease activity while filtering out false positives from other inflammatory conditions.
Solution Approach 2:
The patent introduces complement proteins as intermediary biomarkers that mediate between the immune system's inflammatory response and the diagnostic measurement. These intermediaries (C3, C4, iC3b, sC5b-9) specifically indicate complement-mediated inflammation characteristic of autoimmune flares, providing a precise diagnostic bridge.
2Ease of operation
If laboratory tests are used to estimate flare presence, then treatment decisions can be made, but patients may be erroneously treated or undertreated due to lack of specificity
Solution Approach 1:
The patent implements feedback through monitoring complement protein levels and ratios over time, where changes in these specific biomarkers provide direct feedback on true disease activity. This feedback mechanism enables clinicians to make accurate treatment decisions by responding to genuine flare signals while ignoring non-specific inflammatory changes.
3Productivity
If non-specific tests are used for autoimmune disease monitoring, then clinical trials can proceed, but logistical issues arise due to improper treatment and false positives
Solution Approach 1:
The patent replaces the mechanical system of non-specific clinical assessment and generic inflammatory markers with a biochemical measurement system targeting complement proteins. This substitution provides objective, quantifiable data on true autoimmune activity, eliminating the information loss and logistical problems associated with non-specific monitoring in clinical trials.
Data Source
AI summary
In some embodiments, the present invention provides methods for treating pregnant patients at risk of adverse pregnancy outcome, including, in some embodiments, by measuring one or more of a level of iC3b, intact C3, and total C3.